News

follicular lymphoma, lymphoma

ASH 2021: Long-Term Follow-Up Reveals Superiority of Maintenance Rituximab Therapy Over Retreatment Strategy in Low Tumor Burden Follicular Lymphoma

In a long-term follow-up of the RESORT study, maintenance rituximab (Rituxan) delayed time to first cytotoxic therapy (a substance that kills cells, including cancer cells.

lymphoma

LRF Releases 2022 Public Policy Agenda Outlining Priorities for Year Ahead

The Public Policy Agenda outlines LRF's policy priorities for the year ahead and will direct the efforts of thousands of patient and caregiver advocates across the United States.

lymphoma

What Lymphoma Patients Need to Know About the Approved Preventative COVID-19 Antibody

On December 8, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld, a monoclonal antibody combination of tixagevimab and cilgavimab.

chronic lymphocytic leukemia/small lymphocytic leukemia, lymphoma

Ask the Doctor: What is the difference between a partial response to testing and having undetectable MRD?

Ask the Doctor: What is the difference between a partial response to testing and having…

lymphoma

LRF Scientific Leadership and Investment in Innovative Research Highlighted at 2021 American Society of Hematology Annual Meeting

LRF Scientific Advisory Board Members Joined by Current and Former Grantees at the 63rd ASH Annual Meeting & Exposition

burkitt lymphoma, diffuse large b-cell lymphoma, lymphoma

U.S. Food and Drug Administration Approves Rituximab (RITUXAN) Plus Chemotherapy for Pediatric B-cell Lymphomas

Rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, has been approved in combination with chemotherapy for pediatric patients 6-18 months with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL).

lymphoma

Update Recommendations for Booster Shots

Recommended questions lymphoma patients, survivors, and caregivers can ask their healthcare provider.

lymphoma

COVID-19 Vaccine Updates and FAQs

The Lymphoma Research Foundation (LRF) encourages patients, survivors, and their caregivers to take information and questions back to their individual health care providers as a way of creating a dialogue and partnership about their lymphoma and treatment.

lymphoma, Mantle Cell Lymphoma

Hope Forever and a Day

For more than 23 years, Marla Briskman faced her lymphoma—enduring five relapses and six different treatments. What gave her hope? Incredible treatment advancements and the support of family, friends, and her husband and caregiver, Rickey.

lymphoma

Caregiver Perspectives: Managing The Responsibilities of Caring for a Loved One

A lymphoma diagnosis not only affects the patient, but their caregivers too. LRF Scientific Advisory Board member, Thomas M. Habermann, MD shares some helpful strategies on how to help cope with some of the pressures of caregiving.